26 min listen
Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald
Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald
ratings:
Length:
21 minutes
Released:
Feb 15, 2024
Format:
Podcast episode
Description
On this episode of Cell & Gene: The Podcast, Kite Pharma's Global Head of Technical Operations, Christopher McDonald talks to Host Erin Harris about Kite's recent FDA approval of manufacturing process change resulting in reduced median turnaround time for Yescarta. They talk through the most significant steps Kite took to reach this approval, lessons learned from having worked with the FDA, scaling up technologies for cell therapy manufacturing, and more.
Released:
Feb 15, 2024
Format:
Podcast episode
Titles in the series (76)
State-of-the-Art GMP Manufacturing RNA Cell Therapies with Cartesian's CEO by Cell & Gene: The Podcast